Exeltis Healthcare, Medical Department, Munich, Germany.
Eur Rev Med Pharmacol Sci. 2022 Mar;26(6):1994-1999. doi: 10.26355/eurrev_202203_28348.
This review focuses on the pharmacological and inhibition of the ovulation of progestin-only, estrogen-free contraceptive containing drospirenone in a dosage of 4 mg in a regimen 24/4. The USA and European regulatory authorities have approved it. The molecule has anti-gonadotropic, anti-mineralocorticoid, anti-estrogenic, and antiandrogenic properties. This regime improves the bleeding profile, maintains the plasma E2 levels comparable to the menstrual cycle's early follicular phase, avoids hypoestrogenism, and preserves efficacy despite forgetting the tablet intake as drospirenone has a half lifetime of 30-34 hours. Clinical studies have shown good efficacy, very low cardiovascular side effects, and high acceptability and maintenance of ovulation inhibition after scheduled 24-h delays in pill intake. The molecule is compared to other POP like levonorgestrel or desogestrel.
这篇综述专注于孕激素仅含有屈螺酮 4 毫克剂量和 24/4 给药方案的避孕药的药理学和排卵抑制作用。该药物已获得美国和欧洲监管机构的批准。该分子具有抗促性腺激素、抗盐皮质激素、抗雌激素和抗雄激素特性。这种方案改善了出血模式，使血浆 E2 水平保持与月经周期早期卵泡期相当，避免了雌激素不足，并保持了疗效，尽管忘记了服药，因为屈螺酮的半衰期为 30-34 小时。临床研究表明，该药物具有良好的疗效、极低的心血管副作用，以及在计划的 24 小时延迟服药后，仍能很好地接受和维持排卵抑制。该分子与其他孕激素避孕药（如左炔诺孕酮或去氧孕烯）进行了比较。
